| Host: |
Rabbit |
| Applications: |
WB/IHC |
| Reactivity: |
Human/Mouse |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-IFITM1 (50-125) is suitable for use in Western Blot and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:200-1:2000IHC-P 1:50-1:200 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
IFITM1 |
| Gene ID: |
8519 |
| Uniprot ID: |
IFM1_HUMAN |
| Immunogen Region: |
50-125 |
| Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 50-125 of human CD225/IFITM1 (NP_003632.3). |
| Immunogen Sequence: |
CCLGFIAFAYSVKSRDRKMV GDVTGAQAYASTAKCLNIWA LILGILMTIGFILLLVFGSV TVYHIMLQIIQEKRGY |
| Tissue Specificity | Bone (at protein level). Levels greatly elevated in colon cancer, cervical cancer, esophageal cancer and ovarian cancer. Expressed in glioma cell lines. |
| Post Translational Modifications | Palmitoylation on membrane-proximal cysteines controls clustering in membrane compartments and antiviral activity. |
| Function | IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Inhibits SARS-CoV-2 S protein-mediated syncytia formation. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome. |
| Protein Name | Interferon-Induced Transmembrane Protein 1Dispanin Subfamily A Member 2aDspa2aInterferon-Induced Protein 17Interferon-Inducible Protein 9-27Leu-13 AntigenCd Antigen Cd225 |
| Database Links | Reactome: R-HSA-198933Reactome: R-HSA-909733 |
| Cellular Localisation | Cell MembraneSingle-Pass Membrane ProteinLysosome Membrane |
| Alternative Antibody Names | Anti-Interferon-Induced Transmembrane Protein 1 antibodyAnti-Dispanin Subfamily A Member 2a antibodyAnti-Dspa2a antibodyAnti-Interferon-Induced Protein 17 antibodyAnti-Interferon-Inducible Protein 9-27 antibodyAnti-Leu-13 Antigen antibodyAnti-Cd Antigen Cd225 antibodyAnti-IFITM1 antibodyAnti-CD225 antibodyAnti-IFI17 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
